HF
HLVX

HRT Financial’s HilleVax HLVX Stock Holding History

HRT Financial’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,781
Closed -$195K – 2568
2024
Q1 		$195K Buy
+11,781
New +$188K ﹤0.01% 1778
2023
Q2 		– Sell
-18,026
Closed -$297K – 2787
2023
Q1 		$297K Buy
+18,026
New +$288K ﹤0.01% 1719

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

HRT Financial's HLVX Position: Q2 2024 in Review

HRT Financial sold out of HilleVax (HLVX) in Q2 2024, closing a stake of 11,781 shares — an estimated $195K sold.

HRT Financial first reported a position in HLVX in Q1 2023 and held it in 2 quarters. The position peaked at $297K in Q1 2023. 93 funds tracked by Wall St. Rank hold HLVX as of Q2 2024.

  • HRT Financial reported no remaining HilleVax position as of Q2 2024 after selling out during the quarter.
  • HRT Financial sold 11,781 HilleVax shares in Q2 2024, an estimated $195K.
  • HRT Financial first reported a position in HilleVax in Q1 2023 and held it in 2 quarters.
  • HRT Financial's HilleVax position peaked at $297K in Q1 2023.
  • 93 funds tracked by Wall St. Rank held HilleVax as of Q2 2024.

Based on HRT Financial's 13F filing for Q2 2024, filed 12 Aug 2024.